Non-Hospital-Based Point-of-Care Testing (POCT) Market by Test Type – Home-Based and Self-Testing (Whole Blood Glucose Testing – Integrated Glucose Testing Devices, Implantable Glucose Monitors; Pregnancy and Fertility Testing; Other POC Tests – Cholesterol Testing, Fecal Occult Blood Testing, Drugs of Abuse Testing, Coagulation Testing, Infectious Disease Testing, Cancer Marker Testing); Physician’s Office, Clinical Laboratory and Other Sites – General Chemistry; Hematology (Blood Gas/Electrolyte); Rapid Test Kits – Urinalysis, Whole Blood Glucose, Allergy, Other POC Tests and Forecast 2017-2021

Non-Hospital-Based Point-of-Care Testing (POCT) Market by Test Type – Home-Based and Self-Testing (Whole Blood Glucose Testing – Integrated Glucose Testing Devices, Implantable Glucose Monitors; Pregnancy and Fertility Testing; Other POC Tests – Cholesterol Testing, Fecal Occult Blood Testing, Drugs of Abuse Testing, Coagulation Testing, Infectious Disease Testing, Cancer Marker Testing); Physician’s Office, Clinical Laboratory and Other Sites – General Chemistry; Hematology (Blood Gas/Electrolyte); Rapid Test Kits – Urinalysis, Whole Blood Glucose, Allergy, Other POC Tests and Forecast 2017-2021

Non-hospital-based point-of-care testing (POCT) refers to any diagnostic test administered outside the central laboratory at or near the location of the patient. By performing the sample collection and data analysis steps in the same location POCT cuts down on transport and processing delays, resulting in the rapid feedback of test results to medical decision-makers. Over the past decades the availability and use of POCT have steadily increased in Europe and throughout the international community. POC tests have the potential to improve the management of infectious diseases, especially in resource-limited settings where health care infrastructure is weak, and access to quality and timely medical care is a challenge. These tests offer rapid results, allowing for timely initiation of appropriate therapy, and/or facilitation of linkages to care and referral. Most importantly, POC tests can be simple enough to be used at the primary care level and in remote settings with no laboratory infrastructure.

POCT encompasses a wide variety of procedures and technologies. Current POCT exists for hemoglobin concentrations, five-part differential complete blood count (CBC), pregnancy testing, blood glucose concentrations, cardiac biomarkers, coagulation testing, platelet function, group A streptococcus, HIV testing, malaria screening, and numerous additional applications. POCT devices are used in a wide variety of health care settings. POC tests can potentially empower patients to self-test in the privacy of their homes. e.g. home-based, over-the-counter HIV testing was approved in 2012 by the Food and Drug Administration in the United States. Over the past decades the prevalence and functionality of POCT devices have expanded greatly. In Europe, POCT devices are regulated under the 1998 European Directive 98/79/EC on in vitro diagnostic medical devices. The use of POCT is steadily increasing in the United States, with growth rates expected to average >15% in the coming years.

The global non-hospital-based point-of-care testing market segmentation is based on test type – home-based and self-testing (whole blood glucose testing – integrated glucose testing devices, implantable glucose monitors; pregnancy and fertility testing; other POC tests – cholesterol testing, fecal occult blood testing, drugs-of-abuse testing, coagulation testing, infectious disease testing, cancer marker testing); physician’s office, clinical laboratory and other sites – general chemistry; hematology (blood gas/electrolyte); rapid test kits – urinalysis, whole blood glucose, allergy, other POC tests.

The global non-hospital-based point-of-care testing market segmentation is based on test type – home-based and self-testing (whole blood glucose testing – integrated glucose testing devices, implantable glucose monitors; pregnancy and fertility testing; other POC tests – cholesterol testing, fecal occult blood testing, drugs-of-abuse testing, coagulation testing, infectious disease testing, cancer marker testing); physician’s office, clinical laboratory and other sites – general chemistry; hematology (blood gas/electrolyte); rapid test kits – urinalysis, whole blood glucose, allergy, other POC tests.

The global non-hospital-based point-of-care testing market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global non-hospital-based point-of-care testing market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global non-hospital-based point-of-care testing market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global non-hospital-based point-of-care testing market and profiled in this report include Abaxis, Abbott Laboratories, Accriva Diagnostics, Alere, Alfa Wassermann, Arkray, Danaher (Beckman Coulter, HemoCue, Radiometer), ELITech Group, Helena Laboratories, Instrumentation Laboratory, Menarini Diagnostics, Nova Biomedical, OraSure Technologies, Ortho Clinical Diagnostics, Panasonic Healthcare, Phamatech, Princeton BioMeditech, Quidel, Response Biomedical, Roche Diagnostics, Siemens Diagnostics, Trinity Biotech, and Trividia Health.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Products
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Diagnostic Test Type
    • Indication or Infection Type
    • Technology
    • Diagnostics Application
    • Service Type
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • Device Classification I, II, III, IV
    • Device (FDA, EMEA) Approvals
  8. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  9. Recommendations
  10. References

Non-Hospital-Based Point-of-Care Testing (POCT) Market

1. Test Type
1.1. Home-Based and Self-Testing
1.1.1. Whole Blood Glucose Self-Testing
1.1.1.1. Integrated Glucose Testing Devices
1.1.1.2. Implantable Glucose Monitors
1.1.2. Pregnancy and Fertility Testing
1.1.3. Other Home-based and Self POC Tests
1.1.3.1. Cholesterol Self-Testing
1.1.3.2. Fecal Occult Blood Testing
1.1.3.3. Home Drugs-of-Abuse Testing
1.1.3.4. Coagulation Self-Testing
1.1.3.5. Infectious Disease Self-Testing
1.1.3.6. Cancer Marker Self-Testing
1.2. Physician’s Office, Clinical Laboratory and Other Sites
1.2.1. General Chemistry
1.2.2. Hematology (Blood Gas/Electrolyte)
1.2.3. Rapid Test Kits
1.2.3.1. Urinalysis
1.2.3.2. Whole Blood Glucose
1.2.3.3. Allergy
1.2.4. Other POC Tests

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. Abaxis
3.2. Abbott Laboratories
3.3. Accriva Diagnostics
3.4. Alere
3.5. Alfa Wassermann
3.6. Arkray
3.7. Danaher (Beckman Coulter, HemoCue, Radiometer)
3.8. ELITech Group
3.9. Helena Laboratories
3.10. Instrumentation Laboratory
3.11. Menarini Diagnostics
3.12. Nova Biomedical
3.13. OraSure Technologies
3.14. Ortho Clinical Diagnostics
3.15. Panasonic Healthcare
3.16. Phamatech
3.17. Princeton BioMeditech
3.18. Quidel
3.19. Response Biomedical
3.20. Roche Diagnostics
3.21. Siemens Diagnostics
3.22. Trinity Biotech
3.23. Trividia Health

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*